

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**November 27, 2018**

Date of Report

**MARKER THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**001-37939**

(Commission File Number)

**45-4497941**

(IRS Employer  
Identification No.)

**5 West Forsyth Street  
Suite 200**

**Jacksonville, FL**

(Address of principal executive offices)

**32202**

(Zip Code)

**(904) 516-5436**

Registrant's telephone number, including area code

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On November 27, 2018, the Company issued a press release that the Center for Cell and Gene Therapy at Baylor College of Medicine was to present data from three abstracts at the 60<sup>th</sup> American Society of Hematology Annual Meeting. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.	Description
<a href="#">99.1</a>	<a href="#">Press release issued on November 27, 2018.</a>

---

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 27<sup>th</sup> day of November, 2018.

**MARKER THERAPEUTICS, INC.**  
**(Registrant)**

BY: /s/ Michael Loiacono  
Michael Loiacono  
Chief Accounting Officer

---



**The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60<sup>th</sup>  
American Society of Hematology Annual Meeting**

*--Three abstracts accepted, including oral presentation on multiple myeloma clinical data--*

**Houston, TX – November 27, 2018** – Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today reported that data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018). The studies describe results achieved using multi-tumor antigen specific T cells that were developed at the Baylor College of Medicine in the laboratories of Dr. Ann Leen and Dr. Juan Vera, and exclusively licensed to Marker.

Among the highlights, results from an [ongoing Phase 1 study](#) in patients with multiple myeloma will be reviewed in an oral presentation by Premal Lulla, M.B.B.S., Assistant Professor of Medicine at the Center for Cell and Gene Therapy, Hematology-Oncology, at the Baylor College of Medicine. ASH 2018 will take place in San Diego, CA from December 1-4.

**Oral Presentation Details:**

**Title:** Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma (Abstract # 1014)

**Date:** Monday, December 3, 2018

**Time:** 7:30 p.m. PST (San Diego Convention Center, Ballroom 20D)

**Poster Presentation Details:**

**Title:** Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells (Abstract #1685)

**Date:** Saturday, December 1, 2018

**Presentation Time:** 6:15 p.m. – 8:15 p.m. PST (San Diego Convention Center, Hall GH)

**Title:** Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens (Abstract #2693)

**Date:** Sunday, December 2, 2018

**Presentation Time:** 6:00 p.m. – 8:00 p.m. PST (San Diego Convention Center, Hall GH)

The presentations will contain results beyond what are available in the abstracts on the ASH website.

**About Marker Therapeutics, Inc.**

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and activates the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

Marker is also advancing several innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

For additional information, please call toll free at (904) 862-6490 or visit: [markertherapeutics.com](http://markertherapeutics.com).

To receive future press releases via email, please visit: <https://markertherapeutics.com/email-alerts/>.

Follow us on Twitter [@MRKRTtherapeutic](https://twitter.com/MRKRTtherapeutic), or follow us on [Facebook](https://www.facebook.com/markertherapeutics).

#### **Forward-Looking Statement Disclaimer**

*This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to our multi-tumor antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs and our PolyStart™ program; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and, the timing and success of our clinical trials, as well as Multi-TAA T cell clinical trials conducted by Baylor College of Medicine. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at [www.sec.gov](http://www.sec.gov). The Company assumes no obligation to update the forward-looking statements.*

#### **Contacts**

Marker Therapeutics, Inc.  
Aaron Santos  
(904) 862-6490 EXT. 102  
[investor.relations@markertherapeutics.com](mailto:investor.relations@markertherapeutics.com)

Solebury Trout  
Brad Miles  
(646) 513-3125  
[bmiles@soleburytrout.com](mailto:bmiles@soleburytrout.com)

Amy Bonanno  
(914) 450-0349  
[abonanno@soleburytrout.com](mailto:abonanno@soleburytrout.com)